For UK HealthTech companies
If the NHS can't see where you fit, nobody will say yes
Procurement decisions follow NHSE transformation programmes, ICS plans, and NICE guidance. A product that doesn't explicitly map to those priorities is effectively invisible, regardless of its clinical merit.
Two minutes. Solva follows up with specific market-alignment options.
- Healthtech sales teams reporting prolonged sales cycles and difficulty securing meetings with key NHS decision-makers.
- Product demonstrations failing to resonate because they don't explicitly address current NHS pain points or strategic objectives.
- Significant resources spent on developing features that are not prioritised or funded within the NHS.
- Inability to articulate a clear value proposition that aligns with NHS value-based procurement frameworks.
- Prolonged sales cycles and stalled procurement processes
- Inefficient allocation of sales and marketing resources
- Significant wasted investment in product development and sales efforts
- Missed revenue opportunities from delayed market entry
- Delayed patient access to beneficial technologies
- Suboptimal patient outcomes due to lack of innovation adoption
- Perception of the company as not understanding the NHS landscape
- Damage to brand credibility within the UK healthcare sector
Aligning healthtech products with NHS priorities enhances their appeal to decision-makers and accelerates adoption (NICE, 2025)
Source: https://www.nice.org.uk/news/blogs/5-tips-to-help-get-your-healthtech-product-to-market-fast
Frequently asked questions
Why does this problem persist?
NHS procurement decisions are driven by strategic priorities - NHSE transformation programmes, ICS plans, and NICE guidance. Products that don't explicitly map to these priorities are invisible to decision-makers, regardless of clinical merit.
What is the cost of leaving it unaddressed?
No verified UK data available for specific figures, but misaligned market entry strategies lead to significant wasted time and resources in sales and business development. (Industry consensus)
This is exactly what I do with UK private practices. Answer the few questions above and I'll come back personally with where to start. Paul.